title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
abstract: The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However, regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of patients with lymphoma and enhance the ability to compare outcomes of clinical trials.
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Cheson
authors.forename: Richard I
authors.initials: RI
authors.lastname: Fisher
authors.forename: Sally F
authors.initials: SF
authors.lastname: Barrington
authors.forename: Franco
authors.initials: F
authors.lastname: Cavalli
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Schwartz
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.forename: T Andrew
authors.initials: TA
authors.lastname: Lister
mesh_terms: D019046:Bone Marrow Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007391:International Cooperation; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
references.citation: J Clin Oncol. 2011 May 10;29(14):1844-54
references.pmid: 21482982
references.citation: J Nucl Med. 2010 Sep;51(9):1337-43
references.pmid: 20720036
references.citation: Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):213-9
references.pmid: 18295982
references.citation: J Nucl Med. 2013 Aug;54(8):1244-50
references.pmid: 23674577
references.citation: Cancer Res. 1971 Nov;31(11):1860-1
references.pmid: 5121694
references.citation: J Clin Oncol. 1997 Mar;15(3):1110-7
references.pmid: 9060552
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4643-51
references.pmid: 15837966
references.citation: J Nucl Med. 2005 Jun;46(6):958-63
references.pmid: 15937306
references.citation: J Clin Oncol. 1989 Nov;7(11):1630-6
references.pmid: 2809679
references.citation: J Clin Oncol. 1998 Feb;16(2):603-9
references.pmid: 9469348
references.citation: Ann Oncol. 2003 Jan;14(1):123-30
references.pmid: 12488304
references.citation: Q J Nucl Med Mol Imaging. 2011 Aug;55(4):469-75
references.pmid: 21150862
references.citation: Blood. 1998 May 1;91(9):3340-6
references.pmid: 9558391
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4508-14
references.pmid: 23150698
references.citation: AJR Am J Roentgenol. 2005 May;184(5):1510-3
references.pmid: 15855107
references.citation: Lancet. 2012 May 12;379(9828):1791-9
references.pmid: 22480758
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2143-50
references.pmid: 22421007
references.citation: Blood. 2008 Jan 15;111(2):558-65
references.pmid: 17962512
references.citation: Blood. 2011 Oct 13;118(15):4053-61
references.pmid: 21673350
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5034-43
references.pmid: 15955902
references.citation: Eur Radiol. 1997;7(2):246-8
references.pmid: 9038125
references.citation: J Clin Oncol. 1999 Aug;17(8):2493-8
references.pmid: 10561314
references.citation: J Clin Oncol. 2009 Sep 20;27(27):4555-62
references.pmid: 19652063
references.citation: Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2307-14
references.pmid: 20717826
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Cancer. 2007 Aug 1;110(3):652-9
references.pmid: 17582800
references.citation: Ann Oncol. 2009 Mar;20(3):508-12
references.pmid: 19139176
references.citation: J Clin Oncol. 2012 Dec 20;30(36):4456-7
references.pmid: 23150696
references.citation: Eur J Nucl Med Mol Imaging. 2009 May;36(5):745-50
references.pmid: 19096842
references.citation: Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42
references.pmid: 20428863
references.citation: Mol Imaging Biol. 2010 Apr;12(2):225-32
references.pmid: 19809855
references.citation: Blood. 2004 Sep 1;104(5):1258-65
references.pmid: 15126323
references.citation: J Clin Oncol. 2014 Jun 10;32(17):1776-81
references.pmid: 24799482
references.citation: J Nucl Med. 2011 Mar;52(3):386-92
references.pmid: 21321279
references.citation: Br J Radiol. 2012 Jan;85(1009):81-92
references.pmid: 22096219
references.citation: Cancer Res. 1971 Nov;31(11):1862-3
references.pmid: 5121695
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1415-21
references.pmid: 20142591
references.citation: J Nucl Med. 2010 Jan;51(1):25-30
references.pmid: 20009002
references.citation: Am J Hematol. 2011 Oct;86(10):841-5
references.pmid: 21922524
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi144-8
references.pmid: 24078657
references.citation: Blood. 2012 Mar 1;119(9):2066-73
references.pmid: 22234681
references.citation: J Clin Oncol. 2004 Aug 1;22(15):3046-52
references.pmid: 15284254
references.citation: J Clin Oncol. 2012 Dec 10;30(35):4317-22
references.pmid: 23109699
references.citation: J Clin Oncol. 2007 Feb 10;25(5):579-86
references.pmid: 17242396
references.citation: J Natl Compr Canc Netw. 2012 Dec 1;10(12):1487-98
references.pmid: 23221787
references.citation: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):565-74
references.pmid: 24281821
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2598-607
references.pmid: 21576639
references.citation: J Clin Oncol. 2014 Sep 20;32(27):3048-58
references.pmid: 25113771
references.citation: J Clin Oncol. 2011 Aug 10;29(23):3194-200
references.pmid: 21747087
references.citation: Ann Oncol. 2011 Mar;22(3):739-745
references.pmid: 20813876
references.citation: Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1095-105
references.pmid: 20204358
references.citation: Hepatogastroenterology. 2002 Nov-Dec;49(48):1726-7
references.pmid: 12397778
references.citation: Ann Oncol. 2013 Mar;24(3):561-76
references.pmid: 23175624
references.citation: J Clin Oncol. 2005 Jul 20;23(21):4652-61
references.pmid: 15837965
references.citation: N Engl J Med. 1998 Nov 19;339(21):1506-14
references.pmid: 9819449
references.citation: Ann Oncol. 2006 Jun;17(6):909-13
references.pmid: 16672295
references.citation: J Nucl Med. 2013 May;54(5):683-90
references.pmid: 23516309
references.citation: Cancer Treat Rep. 1977 Sep;61(6):1023-7
references.pmid: 902260
references.citation: J Clin Oncol. 2009 Apr 10;27(11):1781-7
references.pmid: 19273712
references.citation: Br J Radiol. 2002 Jul;75(895):573-7
references.pmid: 12145129
references.citation: J Clin Ultrasound. 1999 Feb;27(2):71-4
references.pmid: 9932251
references.citation: Lancet Oncol. 2008 May;9(5):435-44
references.pmid: 18400558
references.citation: Blood. 2003 May 15;101(10):3875-6
references.pmid: 12531812
references.citation: Ann Oncol. 2000;11 Suppl 1:147-50
references.pmid: 10707798
references.citation: J Clin Oncol. 2007 Feb 10;25(5):571-8
references.pmid: 17242397
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: J Clin Oncol. 1996 Sep;14(9):2427-30
references.pmid: 8823320
references.citation: Blood. 2013 Jul 4;122(1):61-7
references.pmid: 23660958